{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:46:47Z","timestamp":1761709607841,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.repc.2018.05.020","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T17:24:43Z","timestamp":1558373083000},"page":"289-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review"],"prefix":"10.1016","volume":"38","author":[{"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lder","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2018.05.020_bib0230","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.05.020_bib0235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MCA.0000000000000489","article-title":"Comparing mortality between fibrinolysis and primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis of 27 randomized-controlled trials including 11 429 patients","volume":"28","author":"Yanamala","year":"2017","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.repc.2018.05.020_bib0240","first-page":"2017","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.05.020_bib0245","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.repc.2014.02.013","article-title":"Stent for Life in Portugal: this initiative is here to stay","volume":"33","author":"Pereira","year":"2014","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4244\/EIJV12I1A3","article-title":"The Stent for Life Initiative: quo vadis?","volume":"12","author":"Kaifoszova","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.repc.2018.05.020_bib0255","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.05.020_bib0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0002-8703(95)90353-4","article-title":"Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses","volume":"130","author":"Buerke","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2018.05.020_bib0265","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"CURRENT-OASIS 7 Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0270","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0275","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0280","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2018.05.020_bib0285","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.05.020_bib0290","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2011.06.044","volume":"58","author":"Patti","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0295","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0300","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2018.05.020_bib0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.repc.2018.05.020_bib0310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model","volume":"17","author":"van Giezen","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.repc.2018.05.020_bib0315","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.repc.2018.05.020_bib0320","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0325","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-016-0617-y","article-title":"Role of new antiplatelet drugs on cardiovascular disease: update on cangrelor","volume":"18","author":"Marcano","year":"2016","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.repc.2018.05.020_bib0330","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0335","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.amjcard.2008.04.050","article-title":"Incidence of coronary stent thrombosis based on academic research consortium definitions","volume":"102","author":"Applegate","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0340","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2018.05.020_bib0345","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.89.2.596","article-title":"Randomized trial of a GPIIb\/IIIa platelet receptor blocker in refractory unstable angina","volume":"89","author":"Simoons","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2018.05.020_bib0350","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1067\/mhj.2002.123581","article-title":"Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100","volume":"144","author":"Madan","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2018.05.020_bib0355","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","article-title":"Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials","volume":"293","author":"De Luca","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2018.05.020_bib0360","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mhj.2000.106615","article-title":"Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb\/IIIa blockade","volume":"140","author":"Kereiakes","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2018.05.020_bib0365","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab readministration: results of the ReoPro Readministration Registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2018.05.020_bib0370","unstructured":"Summary of Product Characteristics of Tirofiban - Aggrastat 50 mg\/ml Solution for infusion. https:\/\/www.medicines.org.uk\/emc\/product\/566 [accessed April 2018]."},{"key":"10.1016\/j.repc.2018.05.020_bib0375","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0380","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial","volume":"372","author":"Van\u2019t Hof","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.05.020_bib0385","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0390","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2009.08.093","article-title":"Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial","volume":"56","author":"Zeymer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0395","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2009.10.093","article-title":"Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)","volume":"56","author":"Akerblom","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0400","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.amjcard.2012.05.026","article-title":"Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial)","volume":"110","author":"Singh","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2018.05.020_bib0405","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2018.05.020_bib0410","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/asheducation-2006.1.408","article-title":"Think of HIT","author":"Warkentin","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.repc.2018.05.020_bib0415","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0420","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.05.020_bib0425","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0430","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0435","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0440","article-title":"Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial","volume":"354","author":"Leonardi","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.repc.2018.05.020_bib0445","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.05.020_bib0450","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255117309964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255117309964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:49Z","timestamp":1760108869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255117309964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0870255117309964"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2018.05.020","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2018.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}